Kodiak’s Phase 3 eye drug success; Innate discontinues anti-CD20 programnews2026-03-26T14:28:58+00:00March 26th, 2026|Endpoints News|
Limbic aims to show AI beats humans in delivering therapynews2026-03-26T14:19:17+00:00March 26th, 2026|Endpoints News|
Post-Hoc: It’s time to make ACIP serious againnews2026-03-26T14:04:48+00:00March 26th, 2026|Endpoints News|
Oral peptides biotech Pinnacle Medicines gets $89M from US, China investorsnews2026-03-26T11:30:18+00:00March 26th, 2026|Endpoints News|
FDA gives Denali accelerated approval for rare disease drugnews2026-03-25T19:24:58+00:00March 25th, 2026|Endpoints News|
More changes ahead for Takeda with new CEO set to take reinsnews2026-03-25T18:59:59+00:00March 25th, 2026|Endpoints News|
How Seaport is hedging against failure in Phase 2b depression studynews2026-03-25T18:00:28+00:00March 25th, 2026|Endpoints News|
FDA approves Corcept’s Lifyorli for ovarian cancer months earlynews2026-03-25T17:12:25+00:00March 25th, 2026|Endpoints News|
After tumultuous year, Sarepta plots rebound with early data on RNA therapiesnews2026-03-25T15:41:06+00:00March 25th, 2026|Endpoints News|
